Previous Article | Next Article ![]()
Journal of Virology, February 1999, p. 1528-1534, Vol. 73, No. 2
Division of Hematology/Oncology, Department
of Medicine, University of California, San Francisco, School of
Medicine, San Francisco, California 94143
Received 4 September 1998/Accepted 11 November 1998
All human immunodeficiency virus (HIV) isolates can grow readily in
primary CD4+ T cells, but they can be distinguished by
their ability to replicate in macrophages and established T-cell lines.
The macrophage-tropic viruses are generally non-syncytium inducing
(NSI), whereas the T-cell-line-tropic viruses are syncytium inducing
(SI) in cultured cells. We now demonstrate that infection of
CD4+ T cells by NSI and SI viruses shows a differential
effect on production of All isolates of human
immunodeficiency virus (HIV) can infect primary CD4+ T
cells, but they can show a great variability with respect to biological
properties such as replication rate, cytotropism, and syncytium-inducing (SI) capability (20). The viral strains
which infect macrophages are generally nonsyncytium inducing (NSI) and use the chemokine receptor CCR5 for entry. Viral isolates that infect
transformed CD4+ T-cell lines are of the SI phenotype and
use the chemokine receptor CXCR4 (1, 4). Most viruses
isolated in the early stages of infection and during the asymptomatic
phase appear to be of the NSI macrophage-tropic phenotype. The
emergence of T-cell-line-tropic SI viruses later in the course of the
infection generally correlates with CD4+ T-cell decline and
the development of AIDS (7, 35, 36). The molecular basis of
the NSI-SI switch involves modifications in the viral envelope
protein which can change coreceptor usage from CCR5 to CXCR4
and probably to other additional coreceptors (1, 2, 4, 11,
20).
Certain members of the HIV infection itself has also been suggested to be a major factor
influencing immune response by altering the production of certain
cytokines secreted by cells of the immune system (5, 13, 20,
29). In the present study, we have examined the influence of HIV
infection on the production of Viruses.
Four primary HIV-1 isolates (designated SV, NB,
LSP, and EM) were obtained from the peripheral blood mononuclear cells
(PBMC) of clinically healthy HIV-infected subjects by standard
procedures (6). One primary isolate (KP) was recovered from
a subject with AIDS. The biologic phenotype of the SV, NB, and LSP
isolates was NSI as determined in cultured MT-2 cells (18);
EM, KP, and the SF2 strain of HIV-1, isolated from a patient with
candidiasis (21), were of the SI phenotype. EM, KP, and SF2
have a tropism for T-cell lines in vitro and are resistant to the
inhibitory effects of the Cells and cell culture medium.
For cell culture assays, PBMC
were obtained from heparinized whole blood from HIV-seronegative donors
(Irwin Memorial Blood Centers, San Francisco, Calif.) by Ficoll-Hypaque
density gradient centrifugation (Sigma Chemical, St. Louis, Mo.)
(6). CD4+ cells were isolated from the PBMC by
using anti-CD4 antibody-coupled immunomagnetic beads (Dynal Inc., Lake
Success, N.Y.) (26), resulting in more than 95%
CD4+ CD3+ cells (<1% CD8+ cells)
as assessed by flow cytometry (23). CD8+ cells
were isolated with anti-CD8 antibody-coupled immunomagnetic beads from
the PBMC after 3 days of stimulation with phytohemagglutinin (PHA;
Sigma Chemical) (3 µg/ml) (26). Cell cultures were grown in RPMI 1640 medium (BioWhittaker, Walkersville, Md.) supplemented with
10% heat-inactivated (56°C, 30 min) fetal calf serum (FCS) (Gemini
Bioproducts, Calabasas, Calif.), 100 U of recombinant human interleukin
2 (IL-2) (Glaxo Wellcome, Research Triangle Park, N.C.) per ml, 2 mM
L-glutamine, 100 U of penicillin per ml, and 100 µg of
streptomycin (Cell Culture Facility, University of California, San
Francisco) per ml (complete medium).
Cultures of acutely infected peripheral blood cells.
PBMC
and purified CD4+ cells were cultured in the RPMI 1640 complete medium in the presence of 3 µg of PHA per ml for 3 days at a
cell density of 3 × 106/ml. The cells were then
washed and incubated at 37°C for 30 min with Polybrene (Sigma; 2 µg/ml). Subsequently 10 TCID50 of the virus strains SV,
NB, EM, and SF2 per 106 cells or a dilution of the LSP or
KP viruses that yielded similar levels of reverse transcriptase (RT)
activity (16) was used for infection.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Differential Effects of Human Immunodeficiency
Virus Isolates on
-Chemokine and Gamma Interferon Production
and on Cell Proliferation

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
-chemokines and gamma interferon. Infection
by NSI viruses increased production of MIP-1
, MIP-1
, and gamma interferon, whereas infection by SI viruses had no effect or decreased production of these cytokines. Production of RANTES was slightly increased during infection by both virus phenotypes. This differential effect of NSI and SI viruses was observed at the level of
-chemokine mRNA as well as at the level of protein expression. Infection by NSI
viruses also increased CD4+ cell proliferation. These
results may have relevance for a differential role of HIV strains in
AIDS pathogenesis.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
-chemokine family such as MIP-1
, MIP-1
,
RANTES, and MCP-2 have been shown to inhibit infection by NSI but not
SI strains of HIV-1 (10, 14, 15, 25). These chemokines may
produce their anti-HIV effect by blocking virus interaction with CCR5
or down-regulating expression of this receptor (1, 37). The
clinical relevance of chemokines in the transmission and pathogenesis
of HIV is still poorly understood. In addition to competing with HIV
for shared coreceptors, chemokines may play a crucial role in the
attraction of viral target cells to areas of infection and the
generation of an antiviral response (12). Attempts to
correlate levels of chemokine production in vitro with the clinical
stage of infected individuals have produced variable results (3,
8, 24, 32, 38), which may be partially explained by the
differences in the culture conditions and the cell populations examined.
-chemokines and other cytokines. Our
results show a differential effect of NSI and SI viruses on the
production by CD4+ T cells of the
-chemokines MIP-1
and MIP-1
, as well as gamma interferon (IFN-
). In addition,
infection by NSI viruses enhanced CD4+ cell proliferation.
The results could provide insight into the ability of certain viruses
to be preferentially expressed and to establish infection in lymphoid
tissue during primary infection. These effects could play an important
role in the immunopathology of HIV infection.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
-chemokines, MIP-1
, MIP-1
, and
RANTES. The other isolates are chemokine sensitive (25). All
viruses have been cultured only in PBMC. The 50% tissue culture
infectious dose (TCID50) for each virus was determined in
PBMC as described elsewhere (28). In brief, virus was
diluted 10-fold and inoculated onto PBMC plated in 10 replicate wells.
The extent of replication was measured every 3 days in the culture
fluid by a p24 antigen enzyme-linked immunosorbent assay (ELISA). The
final titer was calculated at the peak time of virus production
(28).
70°C. CD14+ cells were not detected in the
CD4+ T-cell cultures (<1% by fluorescence-activated cell
sorting analyses), and the possible contribution of an adherent
population was excluded by transferring the culture to new plates on
days 7 and 10. Viral replication was monitored by measuring RT activity
in the culture fluid (16).
Assays involving gp120 from NSI and SI viruses. PHA-stimulated CD4+ cells were cultured for 2 weeks in the presence of gp120 from an NSI (gp120 Thai clade E) or an SI (SF2 clade B) strain of HIV at 10, 100, and 1,000 ng/ml (strains provided by Susan Barnett, Chiron Corp., Emeryville, Calif.). Cell culture and collection of the supernatants were performed as described above.
Measurement of
-chemokines in the culture supernatants.
The quantity of RANTES, MIP-1
, MIP-1
, IFN-
, and IL-4 in
duplicate culture fluids was determined with solid-phase ELISA kits
from R&D Systems (Minneapolis, Minn.). The heat-inactivated FCS and
recombinant human IL-2, used in cell culture, did not contain any
antigenically cross-reactive RANTES, MIP-1
, or MIP-1
as
determined by ELISA.
Detection and quantitation of mRNA for chemokines. Total cellular RNA was isolated by suspension of CD4+ cells in Trizol (Gibco-BRL, Gaithersburg, Md.) followed by chloroform extraction and isopropanol precipitation. RNA was resuspended in nuclease-free water and quantitated by UV absorbance at 260 nm. RNA (3 µg) from each sample was used for detection and comparative analysis of chemokine-mRNA species by the RiboQuant Multi-Probe RNase protection assay system according to the manufacturer's instructions (Pharmingen, San Diego, Calif.).
Flow cytometry.
Cells from the culture sample were incubated
for 4 h at 37°C with Brefeldin A (Sigma; 1 µg/ml).
Subsequently the cells were fixed and permeabilized with the FIX & PERM
cell permeabilization kit according to the manufacturer's instructions
(Caltag Laboratories, South San Francisco, Calif.). This procedure
gives the antibody access to intracellular structures and retains the
morphological scatter characteristic of the intact cells. Monoclonal
antibody p24 conjugated with fluorescein isothiocyanate (Coulter,
Miami, Fla.) (used at 1 µg/106 cells) was provided
by Alan Landay (Rush Presbyterian-St. Luke's Medical Center, Chicago,
Ill.). Monoclonal antibody for MIP-1
(mouse anti-human
MIP-1
-phycoerythrin) was purchased from Pharmingen. Monoclonal
antibodies to CD4, CD8, and CD14 were obtained from Becton Dickinson
(San Jose, Calif.). To determine the percentage of p24+
cells, a total of 15,000 events/sample were analyzed. Dead cells and
tissue debris were excluded according to forward and side scatter
properties in order to analyze only the population with the morphology
of live cells.
Proliferation by thymidine uptake. Lymphocytes from uninfected and infected cultures on day 13 were resuspended in RPMI 1640 medium with 10% FCS and plated at 105 cells/well in 96-well plates. [3H]thymidine was added to the cultures, and 10 to 16 h later, the amount of radioactivity incorporated was determined in a scintillation counter by standard procedures.
Statistics. Data were analyzed by the Wilcoxon rank-sum test and the Wilcoxon signed-rank test.
| |
RESULTS |
|---|
|
|
|---|
-Chemokine production by uninfected PBMC and CD4+
and CD8+ cells.
To evaluate the effect of HIV
infection on the production of MIP-1
, MIP-1
, and RANTES, we first
examined the pattern of chemokines produced by uninfected cultures of
PBMC or CD4+ or CD8+ T cells previously
stimulated with PHA. Culture supernatants from different time points
were evaluated by ELISA for the levels of MIP-1
, MIP-1
, and
RANTES. As noted before (24), no difference in
-chemokine
production was noted immediately after mitogen stimulation. However, we
were particularly interested in the pattern of chemokine production
after several days of culture, since this period is when virus
production is maximal after acute infection. By day 13 after PHA
stimulation, CD4+ T cells showed a different pattern of
chemokine production from those of CD8+ T cells and PBMC.
The separated CD4+ T cells produced predominantly MIP-1
and MIP-1
(846 ± 518 and 976 ± 728 pg/ml, respectively),
whereas CD8+ T cells and PBMC produced predominantly RANTES
(455 ± 274 and 1,324 ± 621 pg/ml, respectively) (Fig.
1). The similarity in the pattern of
chemokine production between PBMC and purified CD8+ T cells
may be partially explained by CD8+ T cells being the
predominant cell population in the PBMC culture as assessed on day 13 by fluorescence-activated cell sorting analyses (CD8+
CD4
cells, 78.5% ± 4.9%; CD4+
CD8
, 15% ± 1.4%). The potential role of
CD8+ cells in suppressing MIP-1
and MIP-1
production
in PBMC is presently being studied.
|
and MIP-1
, increased progressively during the
course of the 2-week culture. Conversely, the ability of
CD8+ cells and PBMC to produce MIP-1
and MIP-1
remained unchanged, whereas RANTES production increased over the 2-week
period (data not shown).
Effect of infection with NSI and SI isolates of HIV on the
production of MIP-1
, MIP-1
, and RANTES.
PHA-stimulated PBMC
or CD4+ T cells from seronegative donors were acutely
infected with a low input (10 TCID50) of NSI or SI HIV
isolates. The infection of CD4+ cells influenced chemokine
production depending on the viral phenotype used. Infection of the
cells with NSI isolates led to a significant increase in MIP-1
and
MIP-1
production compared to uninfected controls and cultures
infected by SI viruses (P < 0.01); in contrast,
infection with SI isolates generally gave a slight but not significant
reduction in release of MIP-1
and MIP-1
compared to control
uninfected cells (mean values: for MIP-1
, NSI, 3,620 pg/ml; SI, 400 pg/ml; control, 1,018 pg/ml; for MIP-1
, NSI, 3,088 pg/ml; SI, 325 pg/ml; control, 511 pg/ml) (Fig. 2). Both
virus phenotypes increased RANTES production compared to control
uninfected cultures (P < 0.01) although low levels were consistently detected (mean values: NSI, 205 pg/ml; SI, 75 pg/ml;
control, 22 pg/ml) (Fig. 2). Infection of PBMC by either NSI or SI
virus phenotypes did not produce any effect on the levels of production
of these chemokines compared to the levels produced by control cultures
(data not shown).
|
The differential effect on the production of MIP-1
and MIP-1
does not correlate with the extent of virus replication, the percentage
of viable infected cells, or the viral envelope gp120.
The extent
to which a strain of HIV-1 can spread among the cells inoculated in
vitro can be reflected by the kinetics and level of virus replication.
The different effects on chemokine production by NSI and SI isolates
could be related to a differential ability of the virus to replicate
and spread in the cultures of CD4+ T cells. We, therefore,
quantified the level of virus replication by the RT assay and also by
the percentage of infected cells detected by fluorescence analysis for
the intracellular presence of the viral p24 core antigen.
-chemokine production (Fig. 4C). Using dual staining techniques, we determined that the increased expression of MIP-1
and
MIP-1
during NSI virus replication could be found in both p24-positive and p24-negative cells (data not shown).
|
|
, MIP-1
, and RANTES compared to untreated,
uninfected control cultures was detected (data not shown). In this
regard, a concentration of 1,000 ng of gp120 per ml for HIV-2 has been
previously reported to induce
-chemokine production in vitro
(30).
Effect of HIV infection on
-chemokine mRNA expression.
To
investigate further the mechanism of the differential effects on
-chemokine production by NSI and SI viruses, we determined the
levels of mRNA for chemokines in the infected and uninfected CD4+ cell cultures by an RNase protection assay. The levels
of expression of the constitutive genes L32 and
glyceraldehyde-3-phosphate dehydrogenase were included to allow
quantitative comparisons among the different samples. As noted in Fig.
5, infection with the SI isolate KP abolished the expression of mRNA for MIP-1
and MIP-1
as well as
IL-8. In contrast, infection with the NSI viruses LSP and NB resulted
in an increased expression of mRNA for MIP-1
, MIP-1
, and IL-8
compared to the control levels. The mRNA level for RANTES was not
affected by infection with either virus phenotype.
|
Differential effect of NSI and SI HIV strains on the production of
IFN-
.
The release of the
-chemokines MIP-1
, MIP-1
, and
RANTES has previously been associated with a type 1 immune response
(34). We therefore considered the possible differential
effect of NSI and SI isolates on the release of IFN-
and IL-4,
cytokines prototypical of a Th1 and a Th2 response, respectively
(9). IL-4 was not detected in any of the culture fluids,
including control culture fluids (<15 pg/ml). IFN-
production was
enhanced in CD4+ T cells infected with the NSI strains,
whereas it was reduced in the cultures infected with the SI strains
(Fig. 6A). This effect did not correlate
directly with the level of virus replication (Fig. 6B).
|
T-cell proliferation. To examine the possibility that NSI HIV-1 isolates may cause a general stimulation of CD4+ T cells in addition to increasing production of certain cytokines, we measured the proliferation of CD4+ T cells infected by NSI or SI viruses. CD4+ T cells at 13 days after infection were plated in complete medium devoid of IL-2 in the presence of [3H]thymidine, and the amount of radioactivity incorporated was measured after 10 to 16 h. Day 13 was chosen since it corresponds to the time of maximal chemokine production (Fig. 2). The results showed that infection with the NSI isolates generally led to an increase in cell proliferation compared to the uninfected control, whereas infection with SI isolates resulted in a lower level of cell proliferation (Fig. 7).
|
| |
DISCUSSION |
|---|
|
|
|---|
A common finding during the asymptomatic stage of HIV infection is
the presence of macrophage-tropic, NSI viruses in the blood of infected
individuals (7, 35, 36). These viruses are often replaced by
SI T-cell-line-tropic viruses as the infected individual progresses to
disease (7, 20, 35, 36). What event(s) heralds the switch
from the NSI to SI viruses that often precedes the drop in
CD4+ T cells is not known but appears to be a compromise of
the immune system, particularly CD8+ cell antiviral
activity (19, 22). Recently, the
-chemokines, MIP-1
,
MIP-1
, and RANTES, produced by several different cell types, have
been found to inhibit infection of CD4+ cells by NSI but
not by SI viruses (10). The role of these cytokines in HIV
pathogenesis is not yet clear (24).
Although the approaches used in in vitro systems may not mimic directly
the in vivo situation, the present studies were undertaken to determine
whether infection of CD4+ cells by NSI versus SI viruses
could influence
-chemokine production and thus play a role in the
switch from the NSI to SI phenotype that occurs over time.
In the initial studies, it is noteworthy that we found a selective
production of
-chemokines by immune cells after a 2-week period.
Whereas uninfected CD4+ cells preferentially produced
MIP-1
and MIP-1
, CD8+ cells selectively produced
RANTES (Fig. 1). These results contrast with early findings showing no
difference in
-chemokine production measured immediately after
mitogen stimulation (24). These data are important for the
observations made in subsequent studies with infected CD4+
cells. The results showed a differential effect of NSI and SI viruses
on production of the
-chemokines MIP-1
and MIP-1
. At the peak
of virus production, CD4+ cells infected by NSI virus
strains had an increase in production of these
-chemokines, whereas
cells infected by the SI viruses either showed no effect or had reduced
production of these cytokines (Fig. 2). A slight increase in RANTES
production (<200 pg/ml) was noted following infection by both NSI and
SI viruses. This differential effect of NSI versus SI viruses on
MIP-1
and MIP-1
production was not directly related to
differences in level of viral replication, the number of virus-infected
cells, or cell viability (Fig. 3 and 4). The observations support
earlier findings in our laboratory with CD4+ lymphocytes
(24) and by others using infection of macrophages with NSI
strains (33). They differ somewhat from a recent study using
a variety of NSI strains in cultured CD4+ cells
(15). In those experiments, an increase in MIP-1
and MIP-1
was not consistently observed. These earlier results most likely reflect the lack of control for CD4+ cell viability
and number (15). In further support of this differential
effect of NSI viruses on
-chemokine production, the levels of mRNA
for MIP-1
and MIP-1
were altered following virus infection (Fig.
5). We did not detect any effect on chemokine production by using the
HIV-1 envelope gp120, whereas soluble HIV-2 gp120 has been reported
elsewhere to enhance
-chemokine production in vitro (30).
Whether the role of HIV-1 gp120 on chemokine production depends on the
integrity of the virion and on the ability of cross-linking chemokine
receptors (39) remains a possibility meriting further
evaluation. Conceivably, the Tat protein that can increase
transcription of the chemokine IL-8 and other cytokines (5,
31) plays a role in this phenomenon. This possibility is under
further study.
Another unexpected observation was that production of the Th1 cytokine
IFN-
was increased by NSI viruses whereas the Th2 cytokine IL-4 was
not detected by our assays in either infected or control cultures.
IFN-
, associated with a type 1 immune response, might preferentially
elicit cell-mediated immune responses against HIV. The ability to
induce immune activation may constitute a selective advantage for NSI
HIV strains, rendering the host environment more receptive to the
establishment of a productive infection. It would appear most likely
that the increased production of the chemoattractant proteins by NSI
viruses brings more inflammatory cells (containing target
CD4+ T cells) to the site of HIV infection and thus
encourages viral spread. In this sense, the NSI viruses profit from the
effects of the chemokine production. Nevertheless, viral titers could eventually be lowered by the inhibitory activity of
-chemokines on
HIV replication and by other suppressor factors produced by recruited
CD8+ T cells (22). In any case, the NSI variants
of HIV could modulate the host environment in favor of a chronic
persistent infection. The subsequent appearance of SI strains, through
a disruption in this complex balance between virus and host response,
would lead to a faster progression of the disease.
The results of these experiments also indicated an increase in cell proliferation with NSI virus infection. It is known that HIV replicates most efficiently in activated cells (20, 27). Our findings suggest that NSI viruses play a role in activating cells after infection and thereby increase their ability to sustain replicating virus. Whether this activation is mediated directly by the virus or by cytokines released by the virus-infected cells remains to be determined.
In summary, the differential effect of NSI and SI viruses on
CD4+ cell production of MIP-1
and MIP-1
and IFN-
suggests that the virus subtype infecting an individual can influence
the immunologic response. By inducing an inflammatory reaction, cells
are brought to the site of HIV replication and can serve as further
targets for the virus or as antiviral effector cells. Whereas we
expected that the NSI viruses might decrease
-chemokine release and
thus permit enhanced virus replication, the increased production of these cytokines and the induced proliferation of the target cells may
in fact encourage viral spread to fresh CD4+ cells. With
time, chemokine-resistant SI strains would emerge. Whether the
induction by NSI viruses of IFN-
which can enhance antiviral
responses counters this apparent cell proliferation and increased
number of CD4+ cells available for virus infection remains
to be determined. Further studies should uncover how these different
biological effects of NSI versus SI viruses might influence the
antiviral activity of certain therapies and the pathogenic pathway of
HIV infection.
| |
ACKNOWLEDGMENTS |
|---|
This research was supported by a grant from the National Institutes of Health (AI30350). G.G. was the recipient of a fellowship from the Istituto Superiore di Sanita, Rome, Italy. Dan Mourich is the recipient of a fellowship from the California State Universitywide AIDS Research Program.
We thank Michael Luther, Glaxo Wellcome, for providing the ELISA kits used in these studies; Robert Balderas, Pharmingen, for the RNase protection assay kit; and Edward Barker and Carl Mackewicz for helpful comments. Ann Murai and Christine Beglinger are thanked for help in preparation of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, CA 94143. Phone: (415) 476-4071. Fax: (415) 476-8365.
Present address: The Mount Sinai Medical Center, New York, N.Y.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Berger, E. A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11:s3-s16. |
| 2. | Bjorndal, A., H. Deng, M. Jansson, J. R. Fiore, C. Colognesi, A. Karlsson, J. Albert, G. Scarlatti, D. R. Littman, and E. M. Fenyo. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487[Abstract]. |
| 3. | Blazevic, V., M. Heino, A. Ranki, T. Jussila, and K. J. E. Krohn. 1996. RANTES, MIP and interleukin-16 in HIV infection. AIDS 10:1435-1436[Medline]. |
| 4. | Broder, C. C., and R. G. Collman. 1997. Chemokine receptors and HIV. J. Leukocyte Biol. 62:20-29[Abstract]. |
| 5. |
Buonaguro, L.,
G. Barillari,
H. K. Chang,
C. A. Bohan,
V. Kao,
R. Morgan,
R. C. Gallo, and B. Ensoli.
1992.
Effects of the human immunodeficiency virus type 1 tat protein on the expression of inflammatory cytokines.
J. Virol.
66:7159-7167 |
| 6. |
Castro, B. A.,
C. D. Weiss,
L. D. Wiviott, and J. A. Levy.
1988.
Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells.
J. Clin. Microbiol.
26:2371-2376 |
| 7. |
Cheng-Mayer, C.,
D. Seto,
M. Tateno, and J. A. Levy.
1988.
Biologic features of HIV that correlate with virulence in the host.
Science
240:80-82 |
| 8. | Clerici, M., C. Balotta, D. Trabattoni, L. Papagno, S. Ruzzante, S. Rusconi, M. L. Fusi, M. C. Colombo, and M. Galli. 1996. Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 10:1432-1433[Medline]. |
| 9. | Clerici, M., and G. M. Shearer. 1994. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today 15:575-581[Medline]. |
| 10. |
Cocchi, F.,
A. L. DeVico,
A. Garzino-Demo,
S. K. Arya,
R. C. Gallo, and P. Lusso.
1995.
Identification of RANTES, MIP-1alpha, and MIP-1beta as the major HIV-suppressive factors produced by CD8+ T cells.
Science
270:1811-1815 |
| 11. |
Connor, R. I.,
K. E. Sheridan,
D. Ceradini,
S. Choe, and N. R. Landau.
1997.
Change in coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628 |
| 12. |
Cook, D. N.,
M. A. Beck,
T. M. Coffman,
S. L. Kirby,
J. F. Sheridan,
I. B. Prganell, and O. Smithies.
1995.
Requirement of MIP-1 for an inflammatory response to viral infection.
Science
269:1583-1585 |
| 13. | Gessani, S., P. Borghi, L. Fantuzzi, B. Varano, L. Conti, P. Puddu, and F. Belardelli. 1997. Induction of cytokines by HIV-1 and its gp120 protein in human peripheral blood monocyte/macrophages and modulation of cytokine response during differentiation. J. Leukocyte Biol. 62:49-53[Abstract]. |
| 14. |
Gong, W.,
O. M. Howard,
J. A. Turpin,
M. C. Grimm,
H. Ueda,
P. W. Gray,
C. J. Raport,
J. J. Oppenheim, and J. M. Wang.
1998.
Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication.
J. Biol. Chem.
273:4289-4292 |
| 15. |
Greco, G.,
E. Barker, and J. A. Levy.
1998.
Differences in HIV replication in CD4+ lymphocytes are not related to -chemokine production.
AIDS Res. Hum. Retroviruses
14:1407-1411[Medline].
|
| 16. | Hoffman, A. D., B. Banapour, and J. A. Levy. 1985. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 147:326-335[Medline]. |
| 17. |
Kaminsky, L. S.,
T. McHugh,
D. Stites,
P. Volberding,
G. Henle,
W. Henle, and J. A. Levy.
1985.
High prevalence of antibodies to AIDS-associated retroviruses (ARV) in acquired immune deficiency syndrome and related conditions and not in other disease states.
Proc. Natl. Acad. Sci. USA
82:5535-5539 |
| 18. | Koot, M., A. H. V. Vos, R. P. M. Keet, R. E. Y. de Goede, M. W. Dercksen, F. G. Terpstra, R. A. Coutinho, F. Miedema, and M. Tersmette. 1992. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6:49-54[Medline]. |
| 19. | Landay, A. L., C. Mackewicz, and J. A. Levy. 1993. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin. Immunol. Immunopathol. 69:106-116[Medline]. |
| 20. | Levy, J. A. 1998. HIV and the pathogenesis of AIDS, 2nd ed. American Society for Microbiology, Washington, D.C. |
| 21. |
Levy, J. A.,
A. D. Hoffman,
S. M. Kramer,
J. A. Landis,
J. M. Shimabukuro, and L. S. Oshiro.
1984.
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.
Science
225:840-842 |
| 22. | Levy, J. A., C. E. Mackewicz, and E. Barker. 1996. Controlling HIV pathogenesis: the role of noncytotoxic anti-HIV activity of CD8+ cells. Immunol. Today 17:217-224[Medline]. |
| 23. | Levy, J. A., L. H. Tobler, T. M. McHugh, C. H. Casavant, and D. P. Stites. 1985. Long-term cultivation of T cell subsets from patients with acquired immune deficiency syndrome. Clin. Immunol. Immunopathol. 35:328-336[Medline]. |
| 24. |
Mackewicz, C. E.,
E. Barker,
G. Greco,
G. Reyes-Teran, and J. A. Levy.
1997.
Do -chemokines have clinical relevance in HIV infection?
J. Clin. Invest.
100:921-930[Medline].
|
| 25. |
Mackewicz, C. E.,
E. Barker, and J. A. Levy.
1996.
Role of -chemokines in suppressing HIV replication.
Science
274:1393-1395[Medline].
|
| 26. | Mackewicz, C. E., H. W. Ortega, and J. A. Levy. 1991. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J. Clin. Invest. 87:1462-1466. |
| 27. | Margolick, J. B., D. J. Volkman, T. M. Folks, and A. S. Fauci. 1987. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. J. Immunol. 138:1719-1723[Abstract]. |
| 28. | McDougal, J. S., S. P. Cort, M. S. Kennedy, C. D. Cabridilla, P. M. Feorino, D. P. Francis, D. Hicks, V. S. Kalyanaraman, and L. S. Martin. 1985. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J. Immunol. Methods 76:171-183[Medline]. |
| 29. |
Merrill, J. E.,
Y. Koyanagi, and I. S. Y. Chen.
1989.
Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor.
J. Virol.
63:4404-4408 |
| 30. | Neoh, L. P., H. Akimoto, H. Kaneko, T. Hishikawa, H. Hashimoto, S. Hirose, Y. Kaneko, N. Yamamoto, and I. Sekigawa. 1997. The production of beta-chemokines induced by HIV-2 envelope glycoprotein. AIDS 11:1062-1063[Medline]. |
| 31. |
Ott, M.,
S. Emiliani,
C. Van Lint,
G. Herbein,
J. Lovett,
N. Chirmule,
T. W. McCloskey,
S. Pahwa, and E. Verdin.
1997.
Immune hyperactivation of HIV-1 infected T cells mediated by tat and the CD28 pathway.
Science
275:1481-1485 |
| 32. |
Saha, K.,
G. Bentsman,
L. Chess, and D. J. Volsky.
1998.
Endogenous production of -chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro.
J. Virol.
72:876-881 |
| 33. |
Schmidtmayerova, H.,
H. S. L. Nottet,
G. Nuovo,
T. Raabe,
C. R. Flanagan,
L. Dubrovsky,
H. E. Gendleman,
A. Cerami,
M. Bukrinsky, and B. Sherry.
1996.
Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes.
Proc. Natl. Acad. Sci. USA
93:700-704 |
| 34. |
Schrum, S.,
P. Probst,
B. Fleischer, and P. F. Zipfel.
1996.
Synthesis of the CC-chemokines MIP-1 , MIP-1 , and RANTES is associated with a type 1 immune response.
J. Immunol.
157:3598-3604[Abstract].
|
| 35. |
Tersmette, M.,
R. E. Y. de Goede,
B. J. M. Al,
I. N. Winkel,
R. A. Gruters,
H. T. Cuypers,
H. G. Huisman, and F. Miedema.
1988.
Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
J. Virol.
62:2026-2032 |
| 36. |
Tersmette, M.,
R. A. Gruters,
F. de Wolf,
R. E. Y. de Goede,
J. M. A. Lange,
P. T. A. Schellekens,
J. Goudsmit,
H. G. Huisman, and F. Miedema.
1989.
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.
J. Virol.
63:2118-2125 |
| 37. |
Trkola, A.,
W. A. Paxton,
S. P. Monard,
J. A. Hoxie,
M. A. Siani,
D. A. Thompson,
L. Wu,
C. R. Mackay,
R. Horuk, and J. P. Moore.
1998.
Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.
J. Virol.
72:396-404 |
| 38. | Ullum, H., A. Cozzi Lepri, J. Victor, H. Aladdin, A. N. Phillips, J. Gerstoft, P. Skinhoj, and B. K. Pedersen. 1998. Induction of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein 1-beta are associated with a decreased risk of HIV disease progression. J. Infect. Dis. 177:331-336[Medline]. |
| 39. |
Wong, M., and E. N. Fish.
1998.
RANTES and MIP-1 alpha activate stats in T cells.
J. Biol. Chem.
273:309-314 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»